@ceotodaymag @ceotodaymag www.ceotodaymagazine.com CEO Today Magazine @ceo.today /ceo-today f t y l n Connect with the Powerful and In uential. Follow uson social media to receive the latest updates, news and online features on the go. EO T O D A Y
CEO Today Hea l thcare Award s 2022 - 3 - - INTRODUCTION - C EO T O D A Y HEALTHCARE A W A R D S 2 0 2 2 Welcome to the 2022 edition of the CEO Today Healthcare Awards. Healthcare may be the most crucial business sector of the modern age, and this has never been more true than it has in the past two years. As the world bounces back from a global pandemic, it is the leaders in this sector whose efforts have safeguarded our lives and ensured a return to everyday life. This year’s awards publication aims to shine a light on healthcare’s achievers and innovators worldwide, recognising the invaluable contributions their work makes to our lives and their leadership makes to their businesses. Among this year’s winners are The Whiteley Clinic founder Mark Whiteley, EastGate Biotech CEO Rose C Perri and Sidus SA director Serge Bouteleau. The 2022 awards release contains exclusive interviews with each of them, along with extensive profiles on many more of the industry’s leading minds. We at CEO Today are proud to present this special publication. Congratulations to all of our winners.
MarkWhiteley The Whiteley Clinic Serge Bouteleau SIDUS Dermocosmetica Rose C. Perri EastGate Biotech 6 12 16 FEATURED WINNERS
CEO Today Hea l thcare Award s 2022 - UNITED KINGDOM - - 6 - Professor Mark Whiteley The Whiteley Clinic 1 Stirling House Stirling Road Surrey Research Park Guildford GU2 7RF E: mark@thewhiteleyclinic.co.uk “I would like to be recognised as one of the people who changed the public and professional opinion of venous disease and started getting patients the appropriate treatment for their conditions.”
CEO Today Hea l thcare Award s 2022 - UNITED KINGDOM - - 7 - Tell us about your career path. As a young boy, I had two years of being very ill and was in and out of hospital for investigations and surgery. During that time, I had abysmal medical care from the surgeon in charge of my case. In those days, parents were scared to complain about doctors, and so I was unable to do anything but comply. It was then that I decided to go into medicine to ensure no one else was treated the way I was. We had no medicine in my family, my father being an estate agent and my mother looking after five children. However, I was given a grant from Bath City Council to attend King Edward’s School in Bath, which gave me an excellent education that gave me the grades to go to medical school in 1981. I studied medicine at St Bartholomew’s Hospital Medical School and decided on a surgical career. I was appointed to a prestigious “demonstrator in surgery” position, and then to surgical rotations in Bristol and Portsmouth. I won the “Surgeons-inTraining” medal from the Royal College of Surgeons of Edinburgh for work in auditing outcomes from surgery. I moved to Bath for a 2-year research post, resulting in a Master of Surgery degree and the Norman Tanner Medal from the Royal Society of Medicine. Developing a love for research I became a lecturer in surgery at Oxford University from 1995-1998. I was appointed Consultant Vascular Surgeon at Royal Surrey County Hospital in Guildford in 1998. I performed the first endovenous treatment Mark Prof. Steven Whiteley Founder and Executive Chairman of The Whiteley Clinic
CEO Today Hea l thcare Award s 2022 - UNITED KINGDOM - - 8 - for varicose veins in the UK in March 1999, which heralded a revolution in venous surgery. In 2001 I set up The Whiteley Clinic to be a centre of excellence in the treatment of venous disease. I left the NHS in 2005 as my Chief Executive told me that “veins are not in the NHS plan”. Over the next 20 years, The Whiteley Clinic has become recognised as the leading clinic in the treatment of varicose veins, pelvic congestion syndrome (pelvic varicose veins), venous leg ulcers and the new speciality of aesthetic phlebology - cosmetic veins on the face, hands and elsewhere, previously regarded as impossible or difficult to treat. Our investigations and treatments follow The Whiteley Protocol® which is constantly evolving due to our ongoing research programme. I have over 150 peer-reviewed research papers, have written four books and edited another, I review for many journals and lecture widely at international venous conferences. My team has won a host of international and national prizes for research. As a business, our focus is on excellence rather than price. We have spent many years establishing our premier position in the market and are now expanding to capitalise to this work. Our head office, main clinic, and research and training unit are in the Surrey Research Park in Guildford. We have a central London clinic in Bond Street and smaller clinics in Bristol and Bournemouth. We are currently recruiting doctors and vascular technologists as we open more clinics, initially around the UK and then abroad. What have the past couple of years taught you? As with many businesses, the COVID-19 pandemic had a huge initial impact on our business. In the first instance, we were forced to close our clinics by public pressure despite government advice stating that medical clinics should stay open. Once the initial panic settled, a government minister on Radio 4 stated that not all businesses could be supported, and some had closed when they did not need to! Increasing numbers of patients were contacting us with painful legs, swollen legs and other venous problems. Hence we took guidance from Cordell health to become COVID-secure and, keeping the care quality commission (CQC) informed each step of the way, we re-opened in June 2020. This then led us to have two of the most successful years we have ever had. Of the many lessons this experience has taught me, the following are most relevant:
CEO Today Hea l thcare Award s 2022 - UNITED KINGDOM - - 9 - • Businesses are often highly geared to increase profits and growth. However, my stress levels would have been less if I had had more cash to buffer the shock at the beginning of the pandemic. • Although businesses must bow to public pressure to an extent, it is vital to monitor broadcast information to make sure it is relevant and correct. • By concentrating on excellence, there remains a market for a product regardless of the wider economic or social environment. On a personal side, I also realised that I had been spending too much time travelling and lecturing compared to building and running the business. What is the most rewarding part about your job? Nothing is as satisfying as improving patients’ lives, especially when they have been led to believe there is no cure. We see this regularly in different sorts of patients: • Curing those who have had multiple operations for varicose veins as their previous doctors haven’t got to the underlying cause. • Treating pelvic congestion syndrome in females with pelvic pain who have been told there is nothing wrong. • Healing venous leg ulcers in those consigned to compression bandages and not told that there is a surgical cure. • Removing cosmetically damaging veins on the face, hands or breasts in patients who have been told that nothing can be done for them. Although I enjoy the business aspects of running a healthcare business, nothing is as rewarding as changing patients’ lives for the better. What inspires you? I went into venous surgery because I was taught that “varicose veins are only cosmetic” and “varicose veins always come back”. However, both of these statements are incorrect. It is the research that leads to better understanding and treatments that inspires me. This is at the foundation of our approach to patients and The Whiteley Protocol®. This also leads to a love of teaching and training – imparting our research and best practices to other doctors and scientists. Each summer I take on 2 or 3 students who want to go to medical school and give them research projects. This fast-tracks their careers in medicine. I also train doctors both joining our clinic and internationally through The College of Phlebology, that I founded in 2011. What is on your agenda for the coming months? What do you hope to accomplish and what’s your strategy for the future? The Whiteley Clinic has grown organically over 20 years to become internationally recognised as a centre of excellence in venous surgery. Aiming for future expansion, I have prepared the business for the opening of new clinics. The focus is on ensuring new clinics and new staff will still achieve the same excellent results for patients. • I have trademarked The Whiteley Protocol® and it is continually updated, to ensure all patients get the same optimal treatment. • We have training schedules for new staff (doctors and vascular technologists) ensuring they understand the protocol and are proficient in our techniques. By concentrating on excellence, there remains a market for a product regardless of the wider economic or social environment. ❝ ❝
CEO Today Hea l thcare Award s 2022 - 10 - - UNITED KINGDOM - • I have set up the College of Phlebology Venous Registry, to benchmark our results against others and ensure all of our excellent outcomes are maintained. • We have set up the patient services, finance department and IT to allow for future expansion. We are now able to accelerate our expansion plans and have engaged corporate finance accountants to identify possible investment partners with an aim to increase the speed of our roll-out. Over the next year, I expect to have secured appropriate investment to increase the number of clinics in the UK, with a view to overseas expansion in the future. What are your biggest goals? My first goal is to have sufficient clinics throughout the UK to allow easy access to all patients who wish to use our services. Once this is achieved, my next goal is to look at opening international clinics using our brand and protocol. What do you hope your legacy will be? I would like to be recognised as one of the people who changed the public and professional opinion of venous disease and started getting patients the appropriate treatment for their conditions. I cannot think of another medical condition where bad results are tolerated with comments such as “oh yes they always come back”. This would be inconceivable for any other surgical operation I can think about. By using The Whiteley Protocol®, we have shown that we can reduce recurrence rates from varicose vein surgery to the same as if the patient had never had varicose veins at all (i.e. 3.0-4.5% per year rather than the current 30% recurrence per year). By following the same protocol, we can also cure most leg ulcers, which currently cost the country £1 billion a year in dressings that have no permanent effect. Furthermore, we can cure women with pelvic pain and discomfort who have been told that there is nothing wrong with them or that they have “endometriosis”, when in fact they have pelvic congestion syndrome (varicose veins of the pelvis) which is currently not recognised by the majority of doctors in the country including gynaecologists! Currently in the UK, there is no role in the NHS for a Consultant Venous Surgeon or Consultant Venous Specialist. As such, there is no training for this position and medical schools do not train new doctors in venous physiology, pathophysiology, investigations of treatment. Therefore, the ignorance about venous disease continues and patients with venous conditions are treated by those who wish to treat them rather than those who are trained to do so. It will only be by recognising the morbidity associated with venous disease and how this can be improved by training doctors appropriately, that this will change. I would like to think that the College of Phlebology might help in the recognition of venous disease as a true medical speciality. What does this award mean to you? This award is very special to me. Although I have reached the top of my medical field and have won many prizes and awards for my work in Venous Surgery, this award is for my work in making that research and development into a business. Over the years I have come across many excellent doctors and many excellent businessmen and women. However, I have found very few doctors who are both good at their medical career and who also have a good understanding of business – and even fewer business people who understand patient-facing medical businesses. This award means that I have managed to straddle both worlds. I hope that I will be able to pass on my experiences in both medicine and business to those doctors who are interested in doing the same. Nothing is as satisfying as improving patients’ lives, especially when they have been led to believe there is no cure. ❝ ❝
Serge Bouteleau is the executive director of SIDUS Dermocosmetica for Argentina and Uruguay, former president and CEO of Pierre Fabre for both countries, and previously CEO of Brazil and VP General Manager for Aesthetic Division in the USA. Serge was part of a planned expansion, appointed specifically to handle SIDUS’s new dermocosmetic business after the company acquired the Pierre Fabre group in Argentina and Uruguay. After two years of deep local 360-degree project analysis, he succeeded in a global transformation plan for transition and transformation. His experience in studying Leadership Transition at the INSEAD Business School ensured his success, even in the middle of a worldwide health and economic crisis. SIDUS SA has stood among the most important pharmaceutical companies in Argentina for more than 80 years, offering solutions in the healthcare market for the treatment of a wide range of medical conditions in addition to its solutions in the oral care and skin care markets. Contact: Av. Dardo Rocha 986, B1640FSD, Martinez, Province of Buenos Aires, Argentina Tel: +54 11 4318 9627 www.sidus.com.ar www.sidusdermocosmetica.com.ar CEO Today Hea l thcare Award s 2022 - ARGENTINA - - 12 -
What have been some of SIDUS Dermocosmétic’s recent achievements? In the middle of a very competitive dermocosmetic market and strained political, economic and trade market in Argentina, some recent achievements should be highlighted. In 2021, our dermocosmetic product EAU THERMALE AVENE became the number one sales brand in Argentina in its specific segment (Source: IQVIA MAT sales 2021). KLORANE, the Natural Botanical brand, has also become the number one brand in sales in the hair loss dermocosmetic market in Argentina (Source: IQVIA MAT Sales 2021). In addition, in terms of Corporate Social Responsibility (CSR), two specific projects were supported and granted to the Jardin Carlos Thays - Botanical Garden of Buenos Aires to preserve extension plants and educate people to protect natural patrimony and treasure. This project was awarded by the French Argentinian Trade Chamber (CCIFA). Serge Bouteleau Executive Director of SIDUS Dermocosmetica CEO Today Hea l thcare Award s 2022 - ARGENTINA - - 13 - PHARMACEUTICALS LEADER OF THE YEAR
CEO Today Hea l thcare Award s 2022 - ARGENTINA - - 14 - Another CSR project was the initiative for the EAU THERMALE AVENE brand to be used as part of the Pierre Fabre global action: ‘Skin Protect, Ocean Respect’. This is an eco-responsible approach for longterm commitment. Sun care products are a public health matter and also of environmental concern. We are therefore committed to taking up this dual challenge: to offer optimal UVB-UVA protection and minimise our impact on the environment. This specific project in Argentina is focused on the protection and preservation of the fauna and flora of Argentine Patagonia and to educate on plastic damage in oceans and beaches. Sidus Dermoscometica is united with its brands in eco-responsible health and beauty. I am proud of all those accomplishments with my team. What are you currently working on? We are working on many innovative projects: First, we are working towards the major launch of a new ultra broad-spectrum sun filter, TRIASORB™, proven to be safe for human use and eco-friendly for marine biodiversity. This includes a patented sun filter available in a new sun care product marketed under the EAU THERMALE AVENE brand: Intense Protect 50+. TRIASORB™ is the first organic filter with the ability to absorb and reflect the harmful portion of the solar spectrum, which includes UVB, short UVA and long UVA rays, as well as high-energy visible blue light. TRIASORB™ has also been thoroughly tested under experimental conditions to demonstrate that this filter is not toxic for three key species of marine biodiversity: a coral species, a phytoplankton species and a zooplankton species (scientific publications are currently being prepared). This is fully in line with our CSR commitment. Second, we plan to go to market with a specific skin care line under the KLORANE brand that is comprised of more than 80% natural ingredients. This specific range also includes specific and revolutionary products for anti-fatigue in eyes and anti-puffiness. It is a global anti-puffiness, anti-dark circles and illuminating treatment, suitable for all skin tones, which instantly and durably reduces signs of daily fatigue. Day by day, a user’s eyes regain their radiance and signs of fatigue fade away. The product is specifically designed for the most sensitive eyes and contact lens wearers. Third, we are evaluating the launch of an outstanding range of hyaluronic acid dermal fillers. This product is actually one of the best fillers compared to other injectables. It is made of hyaluronic acid—a substance naturally found in the human body. When injected into the face, especially the lips, it produces a soft and natural result. Finally, over the past few years, considerable attention has been given to cannabidiol (CBD), a major nonpsychotropic constituent of cannabis. We are also analysing this opportunity in many market segments. To be successful, a CEO must first have the vision to steer their business in the right direction. They must also be ambitious and optimistic to pursue their set goals. Other qualities include the ability to rally others towards their visions, loyalty to the company and the employee base, confidence in themselves and the company, critical thinking and communication skills – and passion.
CEO Today Hea l thcare Award s 2022 - ARGENTINA - - 15 - What do you hope to achieve in the future? I am a driven person and I work hard to attain my goals. The ability to overcome obstacles and follow things through to completion has always been a strong point of mine, which is why I have managed to thrive in such competitive and complex environments, subjects and markets. I am stimulated by challenges and one of my next targets is to found my own company, maybe one day. However, I am aware that as a perfectionist my delegation skills have improved, and without outstanding teamwork, none of this could be possible. Now, the sky is the limit. What do you hope your legacy will be? “He cared.” That phrase seems so simple but it says so much. I want my legacy to be that I cared about myself, my wife and kids, my family, my friends, my business partners, my community… those with whom I interacted on a daily basis. Caring is where it all starts and ends. If we do not care, we do not love, work hard, dedicate ourselves and do the right thing. In my opinion, each is required to get to the next level. You cannot truly care for your wife and kids if you do not take care of and care for yourself. The same applies for your customers. Unhappy team members will lead to unhappy clients, and then no clients. Caring is making sure you are the most prepared person for everything. ‘We care’ is the first and most important core value. While this is where I am today, I realise that my thoughts on my legacy may evolve as I evolve. For now, my hope for my legacy will continue to shape who I am and how I live my life. It is your legacy that makes you immortal. You care to leave positive and beautiful things behind. What does this award mean to you? I am so honoured to have my work recognised in this way for the second consecutive year. This is going to be a big step in my professional career. I am overwhelmed with gratitude and my self-confidence will be boosted by this certificate. It will also give me more responsibilities for the betterment of my work. This is truly a glorious moment for my whole team and me. I am thankful to all for considering me for this prize. It would be impossible for me without the help and support from my team. I convey my heartiest appreciation to all.
“EastGate wants to be at the forefront of having a positive impact through our Trade Secret Proprietary technology and strive to be the leaders of drugs administered and absorbed via the inner lining of the mouth.” CEO Today Hea l thcare Award s 2022 - USA - - 16 - Rose C. Perri EastGate Biotech Corp. 65 Harbour Square Suite 2203 Toronto, Ontario M5J 2L4 Canada www.eastgatebiotech.com
EastGate Biotech is a biotech company that was founded in order to have an impact on existing treatment paradigms that will influence healthier lifestyles despite facing chronic illnesses. Eastgate is focusing its efforts on altering the delivery ways for well-known drugs, currently administered only by injections, to non-invasive (oral or sublingual) routes. At the present time our technology focuses on the delivery of insulin via a liquid insulin mouth solution, known as Insugin, based on a proprietary composition. The reason for this initial focus is the fact that diabetes is an epidemic and growing exponentially with each year. This leads to the obvious reality that more people will be dealing with this chronic illness. Insugin, our liquid insulin mouth solution, is targeted towards patients with Type 2 diabetes as well as patients with pre-diabetes. These populations represent the largest segment of the global diabetic population with an expected worldwide rising disease prevalence to over 600 million by 2035. It is predicted that early administration of insulin to Type 2 diabetic patients would not only help to control blood glucose but also may significantly decelerate disease progression. Fear of needles and lack of a convenient noninvasive dosage form for insulin delivery may be the main reasons against wide use and early start of insulin administration. This innovation has several resulting effects: a. patients can safely and effectively manage their chronic disease without disease progression; b. the side effects stemming from diabetes such as strokes, heart disease, kidney disease, amputations; to name a few; will be reduced c. the economic effects of diabetes on government and hospital systems globally which presently amount to billions can be reduced and directed towards other financial concerns. We believe that most people have been touched by this disease whether personally or through a family member or via their community. EastGate wants to be at the forefront of having a positive impact through our Trade Secret Proprietary technology and strive to be the leaders of drugs administered and absorbed via the inner lining of the mouth. Insugin is only one example of the potential applications of our technology to aid in the delivery of “hard-to-deliver” drugs. We believe our technology has the ability to be applied to a number of active pharmaceutical ingredients using delivery systems based on nanoemulsions and other combinations of polymers and lipids with surfactants (mixed micelles). The next frontier may include Alzheimer’s disease and autoimmune disease. Whatever path is followed EastGate’s mission will remain the same; aim to improve existing drugs for a better drug performance profile, increase patient compliance and quality of life and lower overall healthcare costs. Rose C. Perri CEO of EastGate Biotech CEO Today Hea l thcare Award s 2022 - USA - - 17 -
IvanaWaller Optimapharm David Loew Ipsen Pharm Britta Fünfstück Paul Hartmann AG Renee Aguiar-Lucander Calliditas Therapeutics AB Tej Tadi MindMaze James Thorburn City and County Healthcare Group Ltd 20 22 24 26 EUROPE 28 30
www.optimapharm.eu With over 20 years of clinical research experience, Ivana Waller has held several executive leadership positions, setting, and executing strategies for global CROs across the USA, Europe, and APAC. Throughout her career, Ivana has developed an extensive global expertise in operational delivery of clinical trials and in leading cross-functional/multicultural teams. A dynamic leader specialized in operational advancement for contract research organizations, rapid expansions, organic growth, acquisitions, and integrations, Ivana also brings living and working experience in USA, Europe, and APAC to the table. Ivana Waller is joining Optimapharm from Advance Clinical, where she has served as Senior Vice President of Global Development and Expansion; Managing Director Europe and Asia Pacific since January 2018. She previously spent 8 years in Clinipace Worldwide, serving as Chief Business Officer, Europe and Middle East from January 2016 till December 2017, and Chief Operating Officer from October 2009 to December 2015. Prior to joining Clinipace Worldwide, Ivana acted as Vice President, Business Operations for more than a decade at MedTrials Inc. in USA. Mrs. Waller holds a BA in Economics at the University of Texas, USA. CEO Today Hea l thcare Award s 2022 - CROATIA - - 20 -
more than 500 million people within reach of your study, and we are currently running 250 active trials in 38 different countries. We believe that the key to a successful, close and collaborative relationship is trust, based on clear and consistent communication. We will listen attentively to your needs and articulate ourselves with straightforward candour and honesty. This provides a robust foundation of shared understanding where everyone’s expectations are met or managed and issues are resolved quickly and openly. We keep our promises. We possess the experience, knowledge and expertise to make sure we are efficient, dependable, realistic and fair. We are prepared to earn our position as your trusted partner through reliable delivery against agreed project goals. We have the track record, so you can rest assured that your project is in safe hands. Mission Leading mid-sized, full-service CRO accross Europe and North America focussed on our People, consistent quality deliver to our Clients, and supporting the development of new therapies to improve and save Patients‘ lives. We deliver on your promises Helping you expedite the development of new medicines, therapies and treatments that advance human health across the globe. Whether a pharmaceutical, biotech or medical device company, we are your ideal pan-European, full-service CRO. Our in-depth expertise and long lasting experience combined with a flexible, and collaborative approach allow us to tailor our responses to each individual study. Our clinical development capabilities span through trial Phases I-IV, across a broad range of therapeutic areas including medical devices. We have an excellent track record for supporting a range of stakeholders in the pharmaceutical industry including sponsors and research institutions at each clinical development phase. Our highly experienced team of experts supports a comprehensive network of 26 strategically located offices throughout Europe. This puts a population of Ivana Waller CEO of Optimapharm CEO Today Hea l thcare Award s 2022 - CROATIA - - 21 -
www.ipsen.com David Loew was appointed as Chief Executive Officer of Ipsen on July 1, 2020. David brings nearly 30 years of leadership and experience across a range of therapeutic areas, including oncology, CNS and cardio-metabolism, as well as consumer healthcare. He has worked in the U.S., European and international markets. He began his career at Coopers & Lybrand and Hewlett Packard in 1990 before joining Roche in 1992. Over the following two decades, David held a variety of positions, including Global Oncology Head, Global Chief Marketing Officer & Head of Global Product Strategy and Region Head, Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President, Commercial Operations Europe, where he was responsible for the prescription, consumer healthcare and generics business across the EU region. In 2016, David was appointed CEO of Sanofi Pasteur Vaccines. David currently serves on the Boards of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and G5 Santé, the federation of French pharmaceutical companies. David earned his BA in Business Administration and MBA from the University of St. Gallen, Switzerland. CEO Today Hea l thcare Award s 2022 - FRANCE - - 22 -
an ambitious and focused external innovation and business development plan to add important new assets to our existing portfolio, with a cumulative firepower of €3 billion over the next four years. We are expanding the scope of our external innovation efforts across all stages of development, including late and early stage deals. Efficiencies are a key part of our financial outlook for 2024 and will support growth with three objectives: invest in the growth of established products; support the launch of new medicines or new indications; and fuel external innovation. Attracting, developing and retaining highly engaged talent is essential, by building on our employees’ strong engagement and supporting their professional development. We nurture a culture of focus and high performance by increasing accountability for faster and better decision-making. In addition, we want to broaden and deepen our expertise as well as fully leverage the collective intelligence of the company. We are accelerating our efforts to truly embrace diversity in all our facets and make Ipsen a more inclusive organization. Our commitment extends to the well-being of all employees, patients, healthcare systems and communities. At Ipsen, we’re dedicated to improving people’s lives and health outcomes. Our 4,500 employees around the world are committed to tackling areas of high unmet medical need to improve the quality of life of patients and caregivers. Ipsen’s vision is to be a leading global mid-size biopharmaceutical company, with a focus on transformative medicines in three key therapeutic areas: oncology, rare disease and neuroscience. Under the overarching theme of Focus. Together. For patients & society, Ipsen is focusing on four strategic priorities to accelerate our innovation and drive positive impact for patients, employees, shareholders and society—a strategy for the short and long term. We are working to maximize the value of our core products. Our objective is to take patient-centricity to the next level by truly impacting medical care and patient outcomes in our therapeutic areas, notably by building a deep understanding of the patient journey. Patient insights are essential to challenge the status quo, while collaboration with healthcare systems can bring about advancements for patients around the world. The most promising assets in our portfolio are accelerated and prioritized. We are also executing David Loew CEO of Ipsen Pharma CEO Today Hea l thcare Award s 2022 - FRANCE - - 23 -
www.hartmann.info A qualified physicist, Britta Fünfstück is the head of the HARTMANN GROUP. The 49-year-old is responsible for corporate strategy, the Transformation Program office, the Infection Management segment with its Risk Prevention and Disinfection divisions, and the KNEIPP subsidiary. Britta Fünfstück’s responsibilities also include the German domestic market and the Digital, Human Resources, Communications, Quality Management and Compliance departments. CEO Today Hea l thcare Award s 2022 - GERMANY - - 24 -
Prevention initiative, HARTMANN brings together all the possibilities, experience and expertise that the company can offer its customers in the prevention of infections.. Our purpose is to improve outcomes for professionals, caregivers and patients. We do this by constantly looking for ways to deliver smart, outcome-focused solutions and improved experiences in both the professional sector and at home. This will ensure we reach our vision - to become a leading player in the global healthcare market and a driving force to constantly advance healthcare for all. We have the customer at the heart of everything we do, continuously striving to meet and exceed customer expectations, to become the preferred partner of choice. We are ONE strong team, trusting, supporting and encouraging each other, working at eye-level passionately towards the common goal. It is an exciting time to work in healthcare. Healthcare faces some tough challenges such as budget cuts, ageing populations, and increases in non-communicable diseases. That means there are plenty of opportunities to shape the healthcare of the future. HARTMANN has challenged healthcare conventions for 200 years and continues to go further with product solutions for hospitals that protect surgical teams and let them and the hospital work more efficiently. HARTMANN offers wound treatments that make health economic sense and bring simplicity to patients and caregivers’ lives. HARTMANN provides discreet solutions for people with incontinence that preserve their dignity. And HARTMANN continues to pioneer disinfection solutions for healthcare professionals all over the world. As a responsibility of the HARTMANN GROUP, our new initiative intends to improve infection prevention in the medical and care sector. Recent events have brought into sharp focus how essential effective protection against infection is — especially in clinics and professional healthcare environments. With the Mission: Infection Britta Fünfstück CEO of Paul Hartmann AG CEO Today Hea l thcare Award s 2022 - GERMANY - - 25 -
www.calliditas.se Before joining Calliditas, Renée Aguiar-Lucander was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée Aguiar-Lucander was the European Group Head and Managing Director at a global investment bank and has more than 12 years’ experience in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of software for financial services. CEO Today Hea l thcare Award s 2022 - SWEDEN - - 26 -
drug development, corporate development and pharmaceutical commercialization. Calliditas is also supported by its Scientific Steering Committee, a highly regarded network of leading experts, that serve as external advisors and investigators on clinical trials. At Calliditas, we are committed to being a responsible corporate citizen by constantly improving the ways in which our business activities have a social, environmental and economic impact. The foundation of our business is our drive to provide access to treatment for people with rare diseases with a high unmet medical need, and our commitment to the highest standard in business ethics is crucial in helping us to strive towards this goal. Calliditas is dedicated to providing a safe, stimulating, and encouraging environment for all our employees. Our success as a company is determined by our ability to operate as a unified team as we work to earn the trust and respect of our co-workers, investors, and ultimately our patients. Our company is built on a foundation of creative, productive and dedicated employees, and we are committed to ensuring that all have an equal opportunity to flourish and actively contribute to our overall mission. Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas’ lead product, developed under the name Nefecon, has been granted accelerated approval by the FDA under the trade name TARPEYO® and conditional marketing authorization by the European Commission under the trade name KINPEYGO®. TARPEYO and Kinpeygo are the first and only treatments approved for IgA nephropathy by the FDA and EMA, respectively. Calliditas also has a pipeline in orphan-focused indications. Calliditas is conducting a Phase 2b/3 clinical trial in primary biliary cholangitis and a Phase 2 proof-of-concept trial in head and neck cancer with its NOX inhibitor product candidate, setanaxib. Calliditas is led by an experienced and dedicated management team with an average of more than 15 years of prior experience in the pharmaceutical industry, including at leading companies such as GlaxoSmithKline, Pfizer and AstraZeneca. The board of directors includes highly qualified researchers, pharmaceutical sector executives and experts in Renee Aguiar-Lucander CEO of Calliditas Therapeutics AB CEO Today Hea l thcare Award s 2022 - SWEDEN - - 27 -
www.mindmaze.com A neuroscientist, engineer, entrepreneur and member of the international advisory board of the Brain Forum, Tej is the founder and CEO of MindMaze. Born to a family of physicians in India, after studying Electronics Engineering, he moved to Switzerland to pursue a masters in computer graphics, followed by a PhD at the Ecole Polytechnique Fédérale de Lausanne (EPFL). His research topic, Neural Mechanisms of the Embodied Self: Merging VR and electrical neuroimaging, was the starting point for his pioneering vision to create a computing platform that captures neural and ambient signatures based on intent. CEO Today Hea l thcare Award s 2022 - SWITZERLAND - - 28 -
Neurorehabilitation and restoration are reliant on experience-dependent plasticity, which can only be harnessed by high-intensity, high-dose behavioral experiences that go beyond traditional rehabilitation. Our movement based digital solutions see patients physically interact with engaging gamified content designed to holistically train and assess motor and cognitive function objectively. Some of our FDA / CE cleared digital therapies are enablers to the current standard of care and others are evidence-based interventions with a novel approach to brain repair. Our custom built AI engine drives the proprietary hardware for bio-sensing, motion capture, haptics and electrical stimulation to create THE universal platform for brain health. MINDMAZE LABS’ Accelerating humanity’s ability to recover, learn and adapt through advanced neurotechnology. A hub of advanced neuroscience, deep tech and innovative engineering, MindMaze Labs’ mission is to improve every aspect of life. By decoding the brain and harnessing its power, our neuro-technology will be the foundation upon which the next generation of human-machine interfaces is built. Exploring the multimodal harmony in neuroscience, computation, analogue, AI, robotics, computer vision, and engineering, we will transformmultiple industries and bring shared control between humans and machines.Safety and performance in transportation. Enhanced training regimes in sports. Fully immersive gaming. A universal solution for brain health. There’s no limit to what we can facilitate and empower. The CogniChip platform is our largest ambition. An operating system that replicates the multimodal synchronization of all sensory inputs the brain experiences, it will serve as the nucleus of all brain inspired computing platforms – reimagining our relationship with technology. Founded in 2012, MindMaze is a global leader in brain technology with a mission to accelerate humanity’s ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, biosensing, engineering, mixed reality and artificial intelligence, we have enhanced the recovery potential of patients with neurological diseases. Combining our FDA cleared and CE marked digital therapeutics with best-in-class motion analytics, AI and cloud technologies, our goal is to create the universal platform for brain health. Expanding our impact beyond healthcare, MindMaze Labs is our enterprising R&D division tasked with bringing our ground-breaking neuroscience to everyday life. By harnessing the power of the brain, our neurotechnology will empower the next generation of human-machine interfaces. In less than ten years, we have transformed care for debilitating neurological diseases. Our plans for the next ten years are just as ambitious. MINDMAZE : HEALTHCARE Our digital therapeutic solutions are addressing some of the most challenging problems in neurology and neurorehabilitation today. Transforming neuro-restoration across the continuum of care, MindMaze Healthcare uses cutting edge neuroscience to maximise the recovery potential of patients with debilitating neurological diseases, and mitigate the impact of ageing on cognition and movement. Deployed in leading centres around the world, our commercially available digital therapeutics for Stroke, Parkinson’s Disease, Alzheimer’s Disease & Dementia are having a profound impact on the lives of patients and caregivers alike. TejTadi CEO of MindMaze CEO Today Hea l thcare Award s 2022 - SWITZERLAND - - 29 -
www.candchealthcare.co.uk James joined the group in May 2017 from Serco, where he was responsible for national and local government services and international business development. He brings a broad range of skills to City and County’s senior management team. James will focus on consolidating the group’s market-leading position and investing in the workforce as well as developing the group’s offerings in the care-at-home and complex nursing care markets. He will also work to support the health and social care integration agenda at a critical time for the sector. CEO Today Hea l thcare Award s 2022 - UNITED KINGDOM - - 30 -
Our operating companies take pride in providing a flexible and outcomes-focused service. To this end, as with meeting personal care needs, we offer support with practical tasks such as shopping, laundry, housework and managing personal affairs. We also help older people to get out of the house and maintain social contact with family and friends, reducing isolation that can affect older people living in the community. Care support for younger adults Across the UK, we support hundreds of younger adults with physical disabilities, mental health issues or learning disabilities, helping them lead as normal lives as possible. Complex care and live-in services Some of our operating companies specialise in providing complex care support to people with profound or multiple disabilities. These types of services are typically intensive and may include healthcare and/or nursing support. A number of such services are provided on a round-the-clock or live-in basis. Support for disabled children Selected operating companies provide tailored care support for children and young adults with disabilities. Such services range from personal care to support with activities outside the home in assisting our younger clients in having the best start to life they can. City & County Healthcare Group is the largest provider of community-based home and social care services in the UK. Every day, our companies help thousands of people with a wide variety of care needs to live independently at home. Established in 2009, we’ve continued to grow steadily, both by acquiring companies of all sizes and winning new business. The majority of our services are commissioned by local authorities (or health and social care trusts in Northern Ireland). But, we also provide services to NHS commissioners along with a growing number of private individuals. Our success has hinged on our commitment to delivering the highest-quality services whilst offering the public purse great value for money. Our Services Our operating companies collectively support tens of thousands of people across the UK, helping them live independently through a range of care support services. Elderly care Sooner or later, most of us will need some sort of help tomaintain our independence as we grow older. Supporting older people with daily living needs, and personal care in particular, is the bread and butter of most of our businesses. Our care workers travel around local communities helping people over 65 to get up in the mornings, wash, dress, prepare and eat meals and take their medicines. James Thorburn CEO of City and County Healthcare Group Ltd CEO Today Hea l thcare Award s 2022 - UNITED KINGDOM - - 31 -
Jorge Moll Rede D’Or Manoela Mitchell Pipo Saúde Michael Held LifeSpeak Inc. Rob Henderson BioTalent Canada Michael Hoey IPSUM Samira Sakhia Grupo Biotoscana Barclay E. Berdan Texas Health Resources Inc Farzad Mostashari Aledade 34 36 38 40 AMERICAS 42 44 46 48
www./ri.rededorsaoluiz.com.br Dr. Jorge Moll is one of the founding partners of Labs D’Or in 1977. He holds a degree in medicine from the Federal University of Rio de Janeiro and is a member of the pediatric cardiology department at SBC and the fellowship of the American Faculty of Cardiology. CEO Today Hea l thcare Award s 2022 - BRAZIL - - 34 -
Founded in 1977 in Rio de Janeiro as Cardiolab, Rede D’Or is the largest integrated health care network in Brazil, with presence in the states of Rio de Janeiro, São Paulo, Pernambuco, Bahia, Maranhão, Sergipe, Ceará, Paraná, Minas Gerais, Mato Grosso do Sul, Paraíba, Alagoas and the Federal District. Focusing on humanized care, team qualification, adoption of new technologies and expansion of care, Rede D’Or is a reference in technical quality and has 69 own hospitals in operation, 3 managed hospitals, and 53 oncology clinics, in addition to complementary services such as blood bank, dialysis and outpatient clinics of various specialties. Rede D’Or also invests in innovation and clinical research, through IDOR (D’Or Research and Education Institute), founded in 2010, in Rio de Janeiro. IDOR is dedicated to the generation of knowledge and training of physicians, researchers, and other health professionals, in order to contribute to the health sector for the benefit not only of the Company and other partners and supporters, but of society as a whole. Patient care is a great differential of the D’Or Oncology group, one of the most complete cancer care networks in the country. There are 53 clinics in the states of Rio de Janeiro, São Paulo, Pernambuco, Sergipe, Maranhão, Ceará, Bahia, Paraná, Paraíba and the Federal District. The synergy between the Rede D’Or and D’Or Oncology favors diagnosis and treatment. The continuous flow of care prevents repeated examinations and reduces the waiting time between appointments and procedures. More than 300 physicians are dedicated to the diagnosis and treatment of all types of cancer, providing world-class care in all units. In 2021, the group performed an average of 40,000monthly visits, applying the different antineoplastic treatments – chemotherapy, target therapy, immunotherapy, hormone therapy, radiotherapy and bone marrow transplantation – to about 9,000 people each month. Rede D’Or also has one of the largest facilities for surgeries with the aid of robots in Brazil. There are 18 advanced robots available in 17 hospitals (Copa Star, Copa D’Or, Quinta D’Or, Barra D’Or, Clínica São Vicente, Santa Helena, DF Star, Vila Nova Star, São Luiz Itaim, São Luiz Morumbi, São Luiz Jabaquara, São Luiz Anália Franco, Hospital Brasil, São Rafael, São Lucas, Esperança Recife, and Hospital Aliança). The technique is minimally invasive and offered in Rede D’Or for procedures in the areas of urology, gynecology, general and bariatric surgery. New areas are under development. Jorge Moll Founder & Chairman of Rede D’Or CEO Today Hea l thcare Award s 2022 - BRAZIL - - 35 -
CEO Today Hea l thcare Award s 2022 - BRAZIL - - 36 - www.piposaude.com.br Manoela Mitchell is co-founder and CEO of Pipo Saúde. Graduated in Economics from the University of São Paulo (USP), she has a specialization in entrepreneurship from Stanford University and worked for seven years in the investment area, working in companies such as Barclays Capital, Temasek and Actis. There, she was delighted with the entrepreneurs who came to present projects to her, in search of capital, and realized that she wanted to be on the other side of the table. Therefore, in 2019, she co-founded Pipo Saúde, which, in 2021, received a contribution of R$100 million, the largest amount ever raised by a woman in Brazil.
CEO Today Hea l thcare Award s 2022 - BRAZIL - - 37 - More technology, less bureaucracy. We are HR’s strategic partner in the management or contracting of corporate health plans. We understand the health conditions of each company and each employee to take care of them individually. As much as technology advances, the health care system does not seem to keep up with this evolution. Instead of simplifying understanding, it is increasingly difficult and complex to make good decisions towards well-being. And it shouldn’t be like that. Health must be accessible and clear to all. Pipo was born to believe that people can find their best health. Guided by the mission of simplifying understanding, navigation and access, we facilitate the management of corporate health benefits to offer more quality of life to people. The Challenge Corporate health is bureaucratic and impersonal. The health system is complex, bureaucratic and often analogical. Empowering companies with data and unburdening their operation allows them time to be strategic and focus on the business while Pipo takes care of employees. The Solution Centralized management of benefits and humanized employee care. We unite the digital and the human. Through our platform, we centralize and digitize the management of health benefits for companies and offer a dedicated Health Team that individualizes care for employees and their dependents. How we transform your healthcare experience • Data-driven health management • Health of your employees transformed into data. • Transform healthcare data into insights to control costs and drive healthcare programs and actions. Health x-ray Visibility regarding the use of benefits, predictability of the evolution of claims and analysis and insights of medical bills. My Health Questionnaire Attention and prevention when identifying behaviors or health situations that may affect the well-being of its employees. Health actions and programs We know the health of your employees through insights from the X-Ray + My Health Questionnaire and we promote actions to take better care of your population. Employee health care Health monitoring and guidance for your employees A team of health guides dedicated to its employees, whether to clarify reimbursements or seek medical advice. Manoela Mitchell Founder & CEO of Pipo Saúde
RkJQdWJsaXNoZXIy Mjk3Mzkz